145 related articles for article (PubMed ID: 32055269)
1. Potential value of V-domain Ig suppressor of T-cell activation for assessing progn osis in cervical cancer and as a target for therapy.
Kuang L; He Y
Int J Clin Exp Pathol; 2020; 13(1):26-37. PubMed ID: 32055269
[TBL] [Abstract][Full Text] [Related]
2. Expression of V-domain immunoglobulin suppressor of T cell activation is associated with the advanced stage and presence of lymph node metastasis in ovarian cancer.
Liao H; Zhu H; Liu S; Wang H
Oncol Lett; 2018 Sep; 16(3):3465-3472. PubMed ID: 30127950
[TBL] [Abstract][Full Text] [Related]
3. VISTA Expression on Immune Cells Correlates With Favorable Prognosis in Patients With Triple-Negative Breast Cancer.
Cao X; Ren X; Zhou Y; Mao F; Lin Y; Wu H; Sun Q
Front Oncol; 2020; 10():583966. PubMed ID: 33505908
[TBL] [Abstract][Full Text] [Related]
4. The Expression Pattern and Clinical Significance of the Immune Checkpoint Regulator VISTA in Human Breast Cancer.
Xie X; Zhang J; Shi Z; Liu W; Hu X; Qie C; Chen W; Wang Y; Wang L; Jiang J; Liu J
Front Immunol; 2020; 11():563044. PubMed ID: 33250890
[TBL] [Abstract][Full Text] [Related]
5. Clinical significance of immune checkpoint proteins in HPV-infected cervical cancer.
Zou W; Huang R; Li P; Liu X; Huang Q; Yue J; Liu C
J Infect Public Health; 2023 Apr; 16(4):542-550. PubMed ID: 36801634
[TBL] [Abstract][Full Text] [Related]
6. Expression of VISTA correlated with immunosuppression and synergized with CD8 to predict survival in human oral squamous cell carcinoma.
Wu L; Deng WW; Huang CF; Bu LL; Yu GT; Mao L; Zhang WF; Liu B; Sun ZJ
Cancer Immunol Immunother; 2017 May; 66(5):627-636. PubMed ID: 28236118
[TBL] [Abstract][Full Text] [Related]
7. High VISTA Expression Correlates With a Favorable Prognosis in Patients With Colorectal Cancer.
Zong L; Yu S; Mo S; Zhou Y; Xiang Y; Lu Z; Chen J
J Immunother; 2021 Jan; 44(1):22-28. PubMed ID: 33086339
[TBL] [Abstract][Full Text] [Related]
8. VISTA expression associated with CD8 confers a favorable immune microenvironment and better overall survival in hepatocellular carcinoma.
Zhang M; Pang HJ; Zhao W; Li YF; Yan LX; Dong ZY; He XF
BMC Cancer; 2018 May; 18(1):511. PubMed ID: 29720116
[TBL] [Abstract][Full Text] [Related]
9. VISTA is an immune checkpoint molecule for human T cells.
Lines JL; Pantazi E; Mak J; Sempere LF; Wang L; O'Connell S; Ceeraz S; Suriawinata AA; Yan S; Ernstoff MS; Noelle R
Cancer Res; 2014 Apr; 74(7):1924-32. PubMed ID: 24691993
[TBL] [Abstract][Full Text] [Related]
10. The Role of V-Domain Ig Suppressor of T Cell Activation (VISTA) in Cancer Therapy: Lessons Learned and the Road Ahead.
Hosseinkhani N; Derakhshani A; Shadbad MA; Argentiero A; Racanelli V; Kazemi T; Mokhtarzadeh A; Brunetti O; Silvestris N; Baradaran B
Front Immunol; 2021; 12():676181. PubMed ID: 34093577
[TBL] [Abstract][Full Text] [Related]
11. V-Domain Ig Suppressor of T Cell Activation (VISTA) Expression Is an Independent Prognostic Factor in Multiple Myeloma.
Mutsaers P; Balcioglu HE; Kuiper R; Hammerl D; Wijers R; van Duin M; van der Holt B; Broijl A; Gregory W; Zweegman S; Sonneveld P; Debets R
Cancers (Basel); 2021 May; 13(9):. PubMed ID: 34066382
[TBL] [Abstract][Full Text] [Related]
12. VISTA expressed in tumour cells regulates T cell function.
Mulati K; Hamanishi J; Matsumura N; Chamoto K; Mise N; Abiko K; Baba T; Yamaguchi K; Horikawa N; Murakami R; Taki M; Budiman K; Zeng X; Hosoe Y; Azuma M; Konishi I; Mandai M
Br J Cancer; 2019 Jan; 120(1):115-127. PubMed ID: 30382166
[TBL] [Abstract][Full Text] [Related]
13. Rationally targeted anti-VISTA antibody that blockades the C-C' loop region can reverse VISTA immune suppression and remodel the immune microenvironment to potently inhibit tumor growth in an Fc independent manner.
Thakkar D; Paliwal S; Dharmadhikari B; Guan S; Liu L; Kar S; Tulsian NK; Gruber JJ; DiMascio L; Paszkiewicz KH; Ingram PJ; D Boyd-Kirkup J
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35131861
[TBL] [Abstract][Full Text] [Related]
14. Structure and Functional Binding Epitope of V-domain Ig Suppressor of T Cell Activation.
Mehta N; Maddineni S; Mathews II; Andres Parra Sperberg R; Huang PS; Cochran JR
Cell Rep; 2019 Sep; 28(10):2509-2516.e5. PubMed ID: 31484064
[TBL] [Abstract][Full Text] [Related]
15. VISTA as a prospective immune checkpoint in gynecological malignant tumors: A review of the literature.
Ren R; Chang X; Chen C; Yu H; Han L
Open Med (Wars); 2023; 18(1):20230866. PubMed ID: 38152334
[TBL] [Abstract][Full Text] [Related]
16. The novel negative checkpoint regulator VISTA is expressed in gastric carcinoma and associated with PD-L1/PD-1: A future perspective for a combined gastric cancer therapy?
Böger C; Behrens HM; Krüger S; Röcken C
Oncoimmunology; 2017; 6(4):e1293215. PubMed ID: 28507801
[TBL] [Abstract][Full Text] [Related]
17. VISTA: A Mediator of Quiescence and a Promising Target in Cancer Immunotherapy.
Yuan L; Tatineni J; Mahoney KM; Freeman GJ
Trends Immunol; 2021 Mar; 42(3):209-227. PubMed ID: 33495077
[TBL] [Abstract][Full Text] [Related]
18. Differential contribution of three immune checkpoint (VISTA, CTLA-4, PD-1) pathways to antitumor responses against squamous cell carcinoma.
Kondo Y; Ohno T; Nishii N; Harada K; Yagita H; Azuma M
Oral Oncol; 2016 Jun; 57():54-60. PubMed ID: 27208845
[TBL] [Abstract][Full Text] [Related]
19. VISTA: A Promising Target for Cancer Immunotherapy?
Tagliamento M; Agostinetto E; Borea R; Brandão M; Poggio F; Addeo A; Lambertini M
Immunotargets Ther; 2021; 10():185-200. PubMed ID: 34189130
[TBL] [Abstract][Full Text] [Related]
20. VISTA inhibitors in cancer immunotherapy: a short perspective on recent progresses.
Wu C; Cao X; Zhang X
RSC Med Chem; 2021 Oct; 12(10):1672-1679. PubMed ID: 34778768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
